Back to Authors

Sagen, Jessica

A5012566800 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 30

The Mayo Clinic Glial Autoimmunity Study: Glial autoantibody (AQP4/MOG/GFAP) serostatus in recurrent longitudinally extensive transverse myelitis (P6.409)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p6.409

The Mayo Clinic Center for MS and Autoimmune Neurology Biorepository (CMSAN): Infrastructure Development (P1.9-069)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p1.9-069

Clinical utility of testing cerebrospinal fluid (CSF) for AQP4-IgG: A guideline to improve physician ordering of AQP4-IgG diagnostic test. (S12.003)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s12.003

Autoimmune AQP4 Channelopathy and Bradycardia: Expanding the NMOSD Spectrum (P5.306)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p5.306

Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum: A Comparison of Two Ethnically Divergent Populations (P3.003)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p3.003

Central Dysregulation of Heart Rate and Blood Pressure in Autoimmune AQP4 Channelopathy: Expanding the neuromyelitis optica spectrum disorder (NMOSD). (S20.008)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s20.008

Placental transmission of AQP4-IgG to neonate from mothers with neuromyelitis optica spectrum disorder (NMOSD) (S20.006)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s20.006

Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) (P6.386)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p6.386

Clinical/ Immunopathological Presentations and Antigen-specific CD8+ T Cell Responses in Paraneoplastic Autoimmune KLHL11 Encephalitis (1185)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1185

NIMG-26. DIFFERENTIATION OF IDH-WILDTYPE GLIOBLASTOMA AND TUMEFACTIVE MULTIPLE SCLEROSIS USING PRE-OPERATIVE BRAIN MRI AND DEEP LEARNING: RIGOROUS AND UNBIASED EXPERIMENTAL DESIGN AND ANALYTICAL APPROACH

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v190-v191

10.1093/neuonc/noad179.0722

Abstract Clinical management of IDH wildtype glioblastoma (GBM) and tumefactive multiple sclerosis (tMS) is drastically different. GBM requires maximal safe resection followed by chemoradiation, while tMS outcome is worsened by surgery and radiotherapy. Misdiagnosis of brain lesions may expose patients to unnecessary anxiety, surgery, or radiotherapy. Noninvasive methods to help with accurate diagnosis of tumor and non-tumor etiologies are needed. tMS subjects were identified by the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology (CMSAN). GBM subjects were matched to tMS by age at diagnosis, index MRI date, and sex. Inclusion criteria included one cm minimal lesion size and pre-operative post-contrast T1 and T2 images available for analysis. To identify potential experimental design bias, MRI technology and clinical characteristics were compared across groups. A 3D-DenseNet121 was used to develop a classification model using prespecified parameters: 600 epochs, batch size 16, learning rate 10-3, cross entropy loss, and AdamW optimizer. The stopping rule was defined as three sequential epoch cross entropy loss < 0.02. Five-fold cross validation (CV) was utilized to obtain an unbiased estimate of predictive performance (overfitting) and sensitivity of the 3D-DenseNet121 algorithm was evaluated. 224 subjects (114 GBM, 110 tMS) were analyzed: 40% male, median age 46. After one round of CV, the average unbiased estimate of sensitivity and specificity for predicting GBM from the final classification model was 0.86 and 0.73, respectively. To assess the reproducibility of the deep learning algorithm (3D-DenseNet121), the exact same CV folds were rerun resulting in average sensitivity and specificity of 0.82 and 0.75, respectively. Obtaining unbiased estimates of model performance using internal validation is critical before evaluating a final model on an external dataset. Understanding sensitivity of a deep learning algorithm is important for model validity. Differentiation of GBM and tMS appears reasonable with MRI; external validation is in progress.